Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected Participants…

Primary: Pin Track Infection Rate Among Research Participants Based on Number of Pins Undergoing Deformity Correction and Traumatic Provisional Fixation — 0; 14 Pins

Primary: Intraoperative Blood Loss — 510; 500 ml — p=0.315

Primary: To Report Positive Versus Negative Hypoxia Among Head and Neck Cancers Using 18F-FMISO Dynamic PET — 135; 0; 26; 0 Participants

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part A — 1; 0; 2; 2 Participants

Primary: Timeline Follow-Back (TLFB) - Number of Participants With Alcohol, Illicit Substance and Cigarette Use During Treatment up to 8 Weeks. Available Date — 8; 12; 9; 4…

Primary: Sensitivity and Specificity of CADence to Detect Stenosis Relative to SPECT Performance, Using Either CT or Standard Angiogram as the Gold Standard — 78; 36 percent…

Primary: Number of Participants With Peri-procedural Myocardial Necrosis — 118; 122 Participants — p=<0.05

Primary: Monthly % Healthy Food Expenditure — 24.8; 26.8; 24.9; 25.7 Percentage of money per month

Primary: Number of Infants and Children With Newly Diagnosed Chronic Medical Conditions (After 28 Days Post Estimated Date of Delivery) — 0; 1; 3 Participants

Primary: Prevalence of SDB in Chronic HF Patients — 3190 Participants

Primary: Opioid Requirements (Morphine Equivalents) — 15; 15; 22.5 morphine milligram equivalent

Primary: Body Weight — -4.6; -4.5; 0.3 Percent change at month 12

Primary: Percentages of Subjects With hSBA ≥ Lower Limit Quantitation (LLQ) Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains.

Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s